Yong Chul Kim1, Mi-Yeon Yu1, Jung Pyo Lee2, Hajeong Lee1, Sang-Il Min3, Jongwon Ha3, Yon Su Kim4,5. 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 2. Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 3. Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea. 4. Department of Medical Science, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. yonsukim@snu.ac.kr. 5. Kidney Research Institute, Seoul National University, Seoul, Republic of Korea. yonsukim@snu.ac.kr.
Abstract
BACKGROUND: Desensitization therapy may enable the patient to get allograft in sensitized recipient or solve the organ shortage in ABO-incompatible relationship in kidney transplantation (KT). However, the graft outcome and morbidity remains unclear. METHODS: We retrospectively analyzed 845 KT patients from January 2010 to February 2016 at Seoul National University Hospital. The patients were divided into three groups as follows: HLA-incompatible (HLAi) group, ABO-incompatible (ABOi) group, and control group. The HLAi group comprised patients who received desensitization therapy due to the presence of donor-specific antibodies (DSAs) or high panel reactive antibodies (PRAs). The ABOi group is defined as those undergoing preoperative desensitization therapy for anti-ABO antibodies. RESULTS: Of the total of 845 recipients, 48 (5.6%) were HLAi KTs and 71 (13.9%) were ABOi KTs, respectively. Pre-emptive KT is done more frequently in ABOi group, therefore, they had shorter dialysis duration than the others. HLAi recipients had a higher proportion of women than the ABOi group and a higher proportion of re-transplantation. During the 38.4 (0.4-76.9) months of follow-up, there were more acute antibody-mediated rejections (AAMRs) in the HLAi (6.7%) and ABOi (8.5%) groups than in the control group (1.9%) (P = 0.001). However, there was no difference in graft survival, patient survival, and annual allograft among three groups. CONCLUSIONS: Despite the higher incidence of AAMRs, HLAi and ABOi KTs showed a favorable graft and patient outcome after desensitization therapy.
BACKGROUND: Desensitization therapy may enable the patient to get allograft in sensitized recipient or solve the organ shortage in ABO-incompatible relationship in kidney transplantation (KT). However, the graft outcome and morbidity remains unclear. METHODS: We retrospectively analyzed 845 KT patients from January 2010 to February 2016 at Seoul National University Hospital. The patients were divided into three groups as follows: HLA-incompatible (HLAi) group, ABO-incompatible (ABOi) group, and control group. The HLAi group comprised patients who received desensitization therapy due to the presence of donor-specific antibodies (DSAs) or high panel reactive antibodies (PRAs). The ABOi group is defined as those undergoing preoperative desensitization therapy for anti-ABO antibodies. RESULTS: Of the total of 845 recipients, 48 (5.6%) were HLAi KTs and 71 (13.9%) were ABOi KTs, respectively. Pre-emptive KT is done more frequently in ABOi group, therefore, they had shorter dialysis duration than the others. HLAi recipients had a higher proportion of women than the ABOi group and a higher proportion of re-transplantation. During the 38.4 (0.4-76.9) months of follow-up, there were more acute antibody-mediated rejections (AAMRs) in the HLAi (6.7%) and ABOi (8.5%) groups than in the control group (1.9%) (P = 0.001). However, there was no difference in graft survival, patient survival, and annual allograft among three groups. CONCLUSIONS: Despite the higher incidence of AAMRs, HLAi and ABOi KTs showed a favorable graft and patient outcome after desensitization therapy.
Authors: Rajiv Saran; Yi Li; Bruce Robinson; Kevin C Abbott; Lawrence Y C Agodoa; John Ayanian; Jennifer Bragg-Gresham; Rajesh Balkrishnan; Joline L T Chen; Elizabeth Cope; Paul W Eggers; Daniel Gillen; Debbie Gipson; Susan M Hailpern; Yoshio N Hall; Kevin He; William Herman; Michael Heung; Richard A Hirth; David Hutton; Steven J Jacobsen; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Yee Lu; Miklos Z Molnar; Hal Morgenstern; Brahmajee Nallamothu; Danh V Nguyen; Ann M O'Hare; Brett Plattner; Ronald Pisoni; Friedrich K Port; Panduranga Rao; Connie M Rhee; Ankit Sakhuja; Douglas E Schaubel; David T Selewski; Vahakn Shahinian; John J Sim; Peter Song; Elani Streja; Manjula Kurella Tamura; Francesca Tentori; Sarah White; Kenneth Woodside; Richard A Hirth Journal: Am J Kidney Dis Date: 2016-03 Impact factor: 8.860
Authors: Babak J Orandi; Xun Luo; Allan B Massie; Jacqueline M Garonzik-Wang; Bonne E Lonze; Rizwan Ahmed; Kyle J Van Arendonk; Mark D Stegall; Stanley C Jordan; Jose Oberholzer; Ty B Dunn; Lloyd E Ratner; Sandip Kapur; Ronald P Pelletier; John P Roberts; Marc L Melcher; Pooja Singh; Debra L Sudan; Marc P Posner; Jose M El-Amm; Ron Shapiro; Matthew Cooper; George S Lipkowitz; Michael A Rees; Christopher L Marsh; Bashir R Sankari; David A Gerber; Paul W Nelson; Jason Wellen; Adel Bozorgzadeh; A Osama Gaber; Robert A Montgomery; Dorry L Segev Journal: N Engl J Med Date: 2016-03-10 Impact factor: 91.245
Authors: Arun Gupta; Victoria Iveson; Mira Varagunam; Stephen Bodger; Paul Sinnott; Raj C Thuraisingham Journal: Transplantation Date: 2008-04-27 Impact factor: 4.939
Authors: Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan Journal: N Engl J Med Date: 2008-07-17 Impact factor: 91.245